COHANCECohance Lifesciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Debt/Equity: 0.10
- • Promoter holding: 64.0%
- • RSI: 56
- • MACD: bullish
- • Price vs EMA21: above
- • 3-month vs NIFTY: +12.6% relative
- • Pullback to 21-EMA signal (setup quality 60%)
Bull case
- • Debt/Equity: 0.10
- • Promoter holding: 64.0%
- • RSI: 56
- • MACD: bullish
Bear case
- • Revenue growth: -23.1% YoY
- • Profit growth: -96.8% YoY
- • Trend strength (ADX): 16
- • Volume: 0.5x 20-day average
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -23.1% YoY
- • Profit growth: -96.8% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹16.07). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.